13 years of historical data (2012–2024) · Healthcare · Biotechnology
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
FibroGen, Inc. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $585M | $1.3B | $2.2B | $37.5B | $32.6B | $83.3B | $92.9B | $97.3B | $86.5B | $33.6B | $46.0B |
| Enterprise Value | $625M | $1.4B | $2.2B | $37.4B | $32.5B | $82.7B | $92.8B | $97.3B | $85.9B | $33.5B | $45.9B |
| P/E Ratio → | -15.63 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 19.75 | 44.72 | 46.07 | 266.32 | 138.34 | 472.54 | 362.04 | 456.71 | 688.24 | 186.93 | 254.17 |
| P/B Ratio | — | — | — | — | 142.08 | 188.74 | 173.50 | 184.04 | 148.49 | 191.70 | 233.52 |
| P/FCF | — | — | — | — | — | 1073.56 | — | — | — | 5732.25 | — |
| P/OCF | — | — | — | — | — | 1021.02 | — | — | — | 4722.57 | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 46.06 | 47.28 | 265.85 | 138.04 | 468.91 | 361.75 | 456.75 | 683.66 | 186.50 | 253.86 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 1065.33 | — | — | — | 5719.20 | — |
Margins and return-on-capital ratios measuring operating efficiency
FibroGen, Inc. earns an operating margin of -507.8%. Operating margins have compressed from -213.9% to -507.8% over the past 3 years, signaling potential cost pressures or competitive headwinds.
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 47.5% | 47.5% | 91.5% | 85.6% | -90.9% | 95.0% | 99.6% | -10.7% | -56.4% | -4.2% | -18.4% |
| Operating Margin | -507.8% | -507.8% | -689.5% | -213.9% | -122.6% | -108.8% | -34.8% | -40.7% | -97.6% | -29.9% | -42.9% |
| Net Profit Margin | -160.6% | -160.6% | -607.3% | -208.7% | -123.3% | -107.4% | -30.0% | -40.6% | -100.4% | -34.3% | -47.4% |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -258.0% | -86.5% | -38.8% | -14.5% | -15.6% | -33.3% | -33.2% | -39.2% |
| ROA | -14.9% | -14.9% | -55.0% | -42.4% | -36.2% | -22.5% | -8.9% | -9.7% | -18.4% | -13.1% | -18.0% |
| ROIC | — | — | — | -500.0% | -137.3% | -109.1% | -13.4% | -24.0% | -174.8% | -33.6% | -37.2% |
| ROCE | -104.8% | -104.8% | -119.0% | -68.0% | -47.6% | -27.1% | -11.6% | -10.7% | -20.0% | -13.3% | -18.8% |
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $40M ($90M total debt minus $50M cash).
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 0.44 | 0.09 | 0.10 | 0.18 | 0.17 | 0.56 | 0.49 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | -0.31 | -1.45 | -0.14 | 0.01 | -0.99 | -0.44 | -0.29 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -8.23 | — | — | — | -13.05 | — |
| Interest Coverage | -18.24 | -18.24 | -39.87 | -209.05 | -268.40 | -79.88 | -31.05 | -7.89 | -12.63 | -5.00 | -7.04 |
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.47x means FibroGen, Inc. can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has declined from 1.80x to 1.47x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.47 | 1.47 | 1.52 | 1.80 | 2.10 | 4.63 | 6.84 | 7.75 | 9.69 | 4.09 | 2.99 |
| Quick Ratio | 1.45 | 1.45 | 1.33 | 1.65 | 1.96 | 4.53 | 6.77 | 7.75 | 9.69 | 4.09 | 2.99 |
| Cash Ratio | 0.38 | 0.38 | 1.08 | 1.54 | 1.80 | 4.21 | 5.19 | 6.98 | 9.52 | 3.89 | 2.70 |
| Asset Turnover | — | 0.14 | 0.11 | 0.23 | 0.30 | 0.21 | 0.30 | 0.24 | 0.14 | 0.38 | 0.38 |
| Inventory Turnover | 4.93 | 4.93 | 0.10 | 0.50 | 14.48 | 0.54 | 0.17 | — | — | — | — |
| Days Sales Outstanding | — | 5.93 | 320.16 | 42.27 | 39.40 | 86.70 | 218.60 | 109.15 | 24.55 | 21.24 | 31.09 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
FibroGen, Inc. returns 0.3% to shareholders annually primarily through dividends.
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 0.3% | 0.2% | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 0.1% | — | — | — | 0.0% | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.3% | 0.2% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $100M | $97M | $94M | $92M | $90M | $87M | $84M | $73M | $63M | $60M |
Compare FGEN with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
| FGENYou | $585M | -15.6 | — | — | 47.5% | -507.8% | — | — | — |
| ARGX | $47B | 60.0 | — | — | 89.6% | -1.0% | 17.4% | -0.5% | — |
| CANF | $14B | -4.4 | — | — | 100.0% | -1206.2% | -134.9% | -448.3% | — |
| AKTX | $13B | -0.0 | — | — | — | — | -179.9% | -172.5% | — |
| ABVX | $10B | -36.7 | — | — | 100.0% | -1602.9% | -149.0% | — | — |
| RAPT | $8B | -2.3 | — | — | — | — | -77.1% | -155.7% | — |
| KYMR | $7B | -24.8 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
| PTGX | $6B | -44.9 | — | 99.9 | — | — | -20.2% | -21.8% | — |
| IMVT | $6B | -10.2 | — | — | — | — | -62.5% | — | — |
| TGTX | $5B | 200.6 | 114.4 | — | 88.3% | 12.7% | 12.2% | 13.3% | 6.0 |
| APGE | $4B | -21.2 | — | — | — | — | -33.2% | -38.3% | — |
| Healthcare Median | — | 23.7 | 13.8 | 18.8 | 65.8% | -6.3% | -37.3% | -15.0% | 3.1 |
Peers based on L4 peer group classification. Compare multiple stocks →
Includes 30+ ratios · 13 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how FGEN stacks up against sector leader argenx SE.
Start ComparisonFibroGen, Inc.'s current P/E ratio is -15.6x. This places it at the 50th percentile of its historical range.
Based on historical data, FibroGen, Inc. is trading at a P/E of -15.6x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
FibroGen, Inc.'s current dividend yield is 0.30%.
FibroGen, Inc. has 47.5% gross margin and -507.8% operating margin.